natgillin/translations-raw huggingface dataset:
Process according to claim 1, characterized in that the condenser is a submerged condenser that is placed horizontally. 
Postupak sukladno zahtjevu 1, naznačen time što je kondenzator uronjeni kondenzator smješten vodoravno.
The method of Claim 9, wherein Y is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1H-pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
Postupak prema zahtjevu 9, naznačen time da Y je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
This additional quantity of water can be useful in order to dilute the sprayed solution, or to alternate different steps of cleaning, with special substances and without them. 
- < dodatni spremnik (415) povezan preko trosmjernog razdjelnika (416), koji sadrži čistu vodu; ova dodatna količina vode može biti korisna radi razrjeđivanja raspršene otopine ili da zamijeni različite korake čišćenja posebnim supstancama i bez njih.
Method according to claim 1, wherein said carbamate salt of an amine is a carbamate salt of a primary amine having two or three primary amine groups. 
Postupak prema zahtjevu 1, gdje je ta karbamatna sol amina karbamatna sol primarnog amina s dvije ili tri primarne skupine amina.
The concentration of the constituents in water may range from 0.25% to 7% by weight, i.e., the dilute solution is comprised of from 93% to 99% by weight water. 
Koncentracija sastojaka u vodi može biti u opsegu od 0.25% do 7 masenih %, tj., razrjeđena otopina se sastoji od 93% do 99 masenih % vode.
Examples of compounds of the invention include: 
Broj objave europskog patenta:
The polypeptide according to any one of claims 1 to 14, or produced according to the process of claim 18 for use in the prevention, treatment or amelioration of a disease selected from a proliferative disease, a tumorous disease, or an immunological disorder. 
Farmaceutski pripravak prema zahtjevu 12 naznačen time što je za uporabu u postupku prevencije, liječenja ili ublažavanja proliferativne bolesti.
formulating non-glycosylated recombinant human G-CSF with an acetate or glutamate buffer and sorbitol to obtain an aqueous buffered G-CSF composition, wherein the amount of G-CSF is in the range of from 0.1 mg/ml to 8.0 mg/ml and wherein said composition has a volume of from 100 ml to 8 l; 
(a) formuliranje neglikoziliranog rekombinantnog ljudskog G-CSF s acetatnim ili glutamatnim puferom i sorbitolom, za dobivanje vodenog puferiranog G-CSF-sastava, pri čemu je količina tog G-CSF u rasponu od 0,1 mg/ml do 8,0 mg/ml 1 pri čemu spomenuti sastav ima volumen od 100 ml do 8 L;
The method of claim 1, wherein the compound is 6,8-(dimethyl-D6)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6,8-dibromo-5,7-(dimetil -D6)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
In a first embodiment, the invention is directed to a two-drug formulation of antiretroviral drugs useful against HIV, comprising the protease inhibitor atazanavir, and cobicistat. 
Formulacija dvoslojne tablete od dva antiretrovirusna lijeka korisna protiv HIV-a koji su a) -atazanavir;i b) -kobicistat u obliku kobicistata na silicij dioksidu.
cutaneous T-cell lymphoma or cutaneous B-cell lymphoma. 
kožni T-stanični limfom ili kožni B-stanični limfom.
is methyl, or an enantiomer, a salt, a N-oxide or a salt of an enantiomer or N-oxide of this compound. 
je metil, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
An isolated antibody or antigen-binding fragment thereof, comprising a variable heavy chain CDR3 having the amino acid sequence set forth as SEQ ID NO: 70 and a variable light chain CDR3 having the amino acid sequence set forth as SEQ ID NO: 59. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 4 ili 5, gdje je protutijelo ili fragment humanizirano i ima varijabilni teški lanac s barem 75% aminokiselina identičnih aminokiselinskoj sekvenci u SEQ ID NO:25, 26, 27 ili 28.
The compound for use according to claim 1, wherein the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, što je spoj odabran 1z skupine koja se sastoji od:
The dosage form of claim 1, wherein the solid dispersion product comprises from about 0.5 to 40% by weight of the pharmaceutically active ingredient, 40 to 97.5% by weight of said at least one pharmaceutically acceptable polymer, 2 to 20% by weight of said at least one solubilizer, and 0 to 15% by weight of additives. 
Oblik za doziranje u skladu s patentnim zahtjevom 1, naznačen time, da kruti disperzijski proizvod sadržava od oko 0,5 do 40 % težinskih udjela farmaceutski aktivnog sastojka, 40 do 97,5 % težinskih udjela navedenog barem jednog farmaceutski prihvatljivog polimera, 2 do 20 % težinskih udjela navedenog najmanje jednog solubilizatora i 0 do 15 % težinskih udjela aditiva.
a cancer that is triple positive for PD-L1, CD8 and IFN-Y; or 
karcinoma koji je trostruko pozitivan za PD-L1, CD8 i IFN-Y; ili
the purification of compounds by preparative thin layer chromatography (PTLC) was conducted on 20×20 cm glass prep plates coated with silica gel, or centrifugal chromatography on a chromatotron using glass rotors coated with silica gel, both commercially available from Analtech; 
(x) pročišćavanje spojeva preparativnom tankoslojnom kromatografijom (PTLC) je provedeno na 20 x 20 cm staklenim preparativnim pločama prevučenim silikagelom, ili centrifugalnom kromatografijom na kromatotronu uporabom staklenih rotora prekrivenim silikagelom, što je oboje raspoloživo od Analtech;
The process as claimed in claim 7, wherein the compound of formula (I) is 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da spoj formule (1) jest 1-(3',4'-diklor-2fluor[1,1"-bifenil]-4-il)-ciklopropankarboksilna kiselina.
Composition for use according to any one of the preceding claims, in form of tablet or capsule. 
Pripravak prema prethodnim zahtjevima, u obliku tablete ili kapsule.
The method of any of the preceding claims, comprising the following steps in the following order: a first anion exchange chromatography, a hydrophobic interaction chromatography, 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, obuhvaća sljedeće korake sljedećim redom: a) prva anionska izmjenjivačka kromatografija, b) hidrofobna interakcijska kromatografija,
A compound having the structure of formula Ia: or a pharmaceutically acceptable salt thereof, wherein: 
HR P20190281 T1 PATENTNI ZAHTJEVI 1. = Spoj koji ima strukturu formule Ia:
In another example, the third user marking cell may be detected based at least in part upon interpolation between: (a) the displacement vector of the detected first user marking cell; and (b) the displacement vector of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom interpolacije između: (a) vektora pomaka detektirane prve ćelije za korisničku oznaku; i (b) vektora pomaka detektirane druge ćelije za korisničku oznaku.
However, all these many efforts have not led to metal packaging, which is capable of being packed in the standard automated packing machines commonly used in these industries for plastic packaging. 
Međutim, sva ova novčana izdvajanja nisu dovela do razvoja metalnog pakiranja koje se može pakirati u standardnim automatiziranim strojevima za pakiranje, koji strojevi se normalno koriste u ovim industrijama za plastično pakiranje.
Pursuant to yet an embodiment, an order of data to be forwarded to a destination is maintained by maintaining an address learning mechanism at the network node and forwarding only such data to the destination for which an address entry is available. 
Postupak prema zahtjevu 7, gdje se poredak podataka koji se šalju na odredište održava tako da se održava mehanizam dobivanja adrese u mrežnom čvoru i tako što se na odredište šalju samo podaci za koje je dostupan unos adrese.
An herbicidal composition according to any on of the previous claims wherein the HPPD-inhibiting herbicide is selected from the group consisting of mesotrione, sulcotrione, tembotrione, 4-Hydroxy-3-[2-(2-methoxyethoxymethyl)-6-trifluoromethylpyridine-3-carbonyl]-bicyclo[3.2.1]oct-3-en-2-one), isoxaflutole and pyrasulfotole. 
Herbicidni pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je herbicid koji inhibira HPPD odabran iz skupine koja sadrži mezotrion, sulkotrion, tembotrion, 4-Hidroksi-3-[2-(2-metoksietoksimetil)-6trifluorometilpiridin-3-karbonil]-biciklo[3.2.1]okt-3-en-2-on), izoksaflutol i pirasulfotol.
It is highly lipophilic and dissociates slowly from opioid receptors. 
Vrlo je lipofilan te sporo disocira s opioidnih receptora.
Use of a composition according to any one of claims 1 to 31, 33, 35, 37, 40, 42, 45, and 47 in the manufacture of a medicament for use in treatment to decrease food intake in an individual. 
Uporaba pripravka u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačena time, da so koristi u izradi lijeka za uporabu u liječenju smanjenjem unošenja hrane kod pojedinca.
The method of claim 1, wherein said subject's pre-administration absolute basophil count is at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 50, at least 60, at least 70, at least 100, at least 200, at least 300, at least 400, or at least 500 basophils/mm3. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-6, naznačeno time da navedeni subjekt prije davanja ima apsolutni broj bazofila od barem 5, barem 10, barem 15, najmanje 20, barem 30, barem 50, barem 60, ili barem 100 bazofila/mm'.
A particularly preferred compound of the invention is selected from the group consisting of: 
Spoj, naznačen time što ga se bira iz skupine koju čine:
wherein Ra represents —CH2-Ar1 or —CH2-Ar1-Ar2, wherein Ar1 and Ar2, which may be identical or different, each represent an aryl or heteroaryl group. 
naznačen time, da Ra predstavlja skupinu odabranu od -CH2-Ar1 i -CH2-Ar1-Ar2, pri čemu su Ar1 i Ar2 definirani u patentnom zahtjevu 1.
The antibody for use of claim 1, where the method comprises administering a dose of about 140 mg. 
Protutijelo ili fragment za upotrebu u skladu s patentnim zahtjevom 1, naznačeno time, da postupak obuhvaća davanja doze od oko 140 mg.
when the tank has a weight W F said tank is in a first position so that said at least one wall of the tank directly contacts said switch (14), and 
- kada spremnik ima težinu Wr, navedeni spremnik je u prvom položaju, tako da je navedena najmanje jedna stijenka spremnika izravno u kontaktu s navedenim prekidačem (14), 1
A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, natural, synthetic or semisynthetic oils such as peanut oil and olive oil, glycerine or water with flavouring, sweetener and/or colouring agent. 
Pripravak u obliku sirupa općenito će sadržavati suspenziju ili otopinu predmetnog spoja ili soli u tekućem nosaču, na primjer, etanolu, prirodnim, sintetskim ili polusintetskim uljima, primjerice ulju kikirikija i maslinovom ulju, glicerinu ili vodi sa sredstvima za poboljšavanje ukusa, sladilima i/ili bojilima.
is chosen from hydrogen, hydroxyl, optionally substituted lower alkyl, phosphate, sulfate, -OR7, a protecting group, and a saccharide; 
je odabran od vodika, hidroksila, po izboru supstituirana alkilna skupina koja ima 1 do 4 atoma ugljika, fosfat, sulfat, -OR7, zaštitna skupina, te saharid;
A pharmaceutical composition as claimed in claim 5, wherein said antibacterial agent is selected from the group consisting of: clarithromycin, azithromycin, erythromycin, telithromycin, solithromycin, clindamycin, the streptogramin combination quinupristin-dalfopristin, eravacycline, minocycline, omadacycline, rifampin, rifabutin, rifalazil, fusidic acid, mupirocin, the oxazolidinones tedizolid and linezolid, vancomycin, dalbavancin, oritavancin, telavancin, the fluoroquinolones moxifloxacin, delafloxacin and avarafloxacin, and the folate synthesis inhibitor trimetoprim. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time da je navedeno antibakterijsko sredstvo odabrano iz skupine koju čine: klaritromicin, azitromicin, eritromicin, telitromicin, solitromicin, klindamicin, kombinacija streptogramina kinupristin-dalfopristin, eravaciklin, minociklin, omadaciklin, rifampin, rifabutin, rifalazil, fusidna kiselina, mupirocin, oksazolidinoni tedizolid i linezolid, vankomicin, dalbavancin, oritavancin, telavancin, fluorokinoloni moksifloksacin, delafloksacin i avarafloksacin, te inhibitor sinteze folata trimetoprim.
Nitric oxide bioavailability appears to be reduced in reperfusion, which is likely due to a decline in endothelial NO production and an increased inactivation of NO by endothelial-cell-derived O2−. 
Čini se, da je biološka raspoloživost dušikovog oksida smanjena u reperfuziji, a to je vjerojatno zbog opadanja endotelne proizvodnje NO 1 povećane inaktivacije NO s O; koji nastaje iz endotelne stanice.
Aclidinium in free or pharmaceutically acceptable salt form for use according to claim 11 or 12, said use further comprising administering an effective amount of one or more additional active agents selected from B2-agonists, PDE IV inhibitors and corticosteroids. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 11 ili 12, pri čemu se spomenuta primjena dalje sastoji od davanja djelotvorne količine jedne ili više dodatnih aktivnih tvari odabranih iz B2 agonista, inhibitora PDE IV 1 kortikosteroida.
The tablet according to any of claims 1 to 9, comprising ulipristal acetate 6 to 12 wt%, lactose monohydrate 71 to 87 wt%, povidone 4.5 to 5.5 wt%, croscarmellose sodium 4.5 to 5.5 wt% and magnesium stearate 1 to 4 wt%. 
Tableta prema bilo kojem od zahtjeva 1 do 9, koja sadrži ulipristal acetat 6 do 12 tež%, laktozu monohidrat 71 do 87 tež%, povidon 4.5 do 5.5 tež%, kroskarmelozu natrij 4.5 do 5.5 tež% i magnezijev stearat 1 do 4 tež%.
Examples of suitable surface-active agents include: anionic surfactants such as sodium dodecyl sulphate (sodium lauryl sulphate); docusate sodium; cationic surfactants such as cetrimide, benzethonium chloride, cetylpyridinium chloride and lauric acid; nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters, e.g. 
Formulacija prema zahtjevu 14, naznačena time da je površinski aktivno sredstvo odabrano iz skupa koji čine: natrijev dodecil sulfat (natrijev lauril sulfat); natrijev dokuzat; cetrimid; benzetonij klorid; cetilpiridinij klorid; laurinska kiselina; polioksietilen alkil eteri; polioksietilen sorbitan esteri masne kiseline, npr.
further wherein X10 is an amino acid covalently attached to a C12-C18 acyl or alkyl group, or when X10 is Tyr, the peptide comprises at position 40 an amino acid covalently attached to a C12 to C18 acyl or alkyl group, and the peptide optionally comprises Gly at position 41. 
Xyo je aminokiselina kovalentno vezana na C12-C18 acilnu ili alkilnu skupinu, ili kada je X;g Tyr, peptid na položaju 40 sadrži aminokiselinu kovalentno vezanu na C12 do C18 acilnu ili alkilnu skupinu, gdje peptid može sadržavati Gly na položaju 41.
A method for producing an antibody molecule composition, comprising 
Postupak proizvodnje pripravka s molekulom protutijela, koji se sastoji u
Process for the preparation of compounds of formula (I) according to Claims 1-11 and solvates, salts and stereoisomers thereof, characterised in that a compound of formula (II) wherein R1, R2 and B1 have the meanings indicated in claim 1 and X is Cl, Br or I, is reacted in a Suzuki reaction with a boronic acid derivative B2-B(OH)2, in which B2 has the meaning indicated in claim 1, and/or a base or acid of the formula I is converted into one of its salts. 
Postupak za dobivanje spojeva formule (I) prema zahtjevima 1-11 1 njegovih solvata, soli i stereoizomera, naznačen time da spoj formule (II) HR P20120549 T1 formula (Il) pri čemu R', R* i B' imaju značenja navedena u zahtjevu 1 i X is Cl, Brili I, reagira u Suzukijevoj reakciji sa derivatom boronske kiseline B'-B(OH),, gdje B* ima značenje navedeno u zahtjevu 1, ifili baza ili kiselina formule I je pretvorena u jednu od njegovih soli.
Preferably the third ring member is fixed in use to prevent rotation of the third ring member. Preferably, the third ring member also comprises a limiting mechanism to limit free rotation of the second ring member relative to the third ring member about the common axis. 
Brojač prema bilo kojem zahtjevu 1 do 10, naznačeno time da treći prstenasti element (1502) sadrži mehanizam ograničenja (1506) kako bi se ograničila slobodna rotacija spomenutog drugog prstenastog elementa (202), (1510) u odnosu na spomenuti treći prstenasti element oko spomenute zajedničke osi.
For the preparation of sustained-release compositions a fluidization apparatus of Glatt GPCG1 type is equipped with a bottom spraying Wurster insert, and 500 g of the above product fraction were fed into the container. 
Za priređivanje smjesa s produženim otpuštanjem, uređaj za fluidiziranje tipa Glatt GPCGI1 opremljen je Wurster umetkom za donje raspršivanje i u spremnik je stavljeno i 500 g gore navedene frakcije produkta stavljeno je u spremnik.
More specifically, RAM memory 9a, 9b is divided into two memory banks, a work memory and a test memory physically separate from each other. 
Određenije, RAM memorija 9a, 9b je podijeljena u dvije memorijske banke, radnu memoriju i testnu memoriju, fizički odijeljene jedna od druge.
A compound represented by the formula 
Spoj prikazan formulom [image]
Item-2) Device according to item 1 wherein the auger has a circumference and the reservoir interfaces with only a portion of the circumference of the auger at the bore/reservoir interface. 
Točka-2) = Uređaj prema točki 1 pri čemu svrdlo ima obodnicu i spremnik je u kontaktu samo s dijelom obodnice svrdla na međupovršini cilindrična šupljina/spremnik.
The immunogenic composition according to claim 19, further comprising PilA from Haemophilus influenzae. The immunogenic composition of claim 20 wherein Protein E from Haemophilus influenzae and PilA from Haemophilus influenzae are present as a fusion protein. 
Imunogeni pripravak u skladu s patentnim zahtjevom 8-9, naznačen time što dodatno sadrži antigene iz bakterije Haemophilus influenzae Protein E, PilA ili Protein E i PilA kao fuzijski protein.
The close proximity of the fire cone to the aerosol generator after a few puffs, together with the insulating means, results in high heat delivery both during puffing and during the relatively long period of smolder between puffs. 
Velika blizina platnenog konusa sa generatorom aerosola poslije nekoliko dimova, zajedno sa izolacijskim sredstvom, dovodi do visoke isporuke topline i za vrijeme uvlačenja dimova i za vrijeme relativno kratkog perioda tinjanja između dimova.
Further, the material is sieved through mesh #100. m.p. range: 223-227° C. 
Nadalje, materijal je prosijan kroz sito # 100. m.p. raspon: 223-227 *C
is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C3-8 cycloalkyl-C1-6 alkyl group, an optionally substituted aryl group, an optionally substituted ar-C1-6 alkyl group, an optionally substituted acyl group, an optionally substituted heterocyclic group or an optionally substituted heterocyclic C1-6 alkyl group; 
je atom vodika, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana C3-8 cikloalkil-C1-6 alkilna skupina, po izboru supstituirana arilna skupina, po izboru supstituirana ar-C1-6 alkilna skupina, po izboru supstituirana acilna skupina, po izboru supstituirana heterociklička skupina ili po izboru supstituirana heterociklička C1-6 alkilna skupina;
Figure 6 shows the proportion of total IL-2 which could be pelleted by centrifugation in the seven samples, and a large increase is seen at the lowest SDS concentration whereas the higher concentrations are essentially constant. 
Slika 6 pokazuje razmjer ukupnog IL-2 koji je mogao biti peletiran centrifugiranjem u sedam uzoraka, a jako veliko povećanje je viđeno pri najnižoj koncentraciji SDS, dok su naprotiv, više koncentracije u biti konstantne.
9), wherein X35 is a residue of an achiral amino acid, said amino acid residues of the sequence optionally including side chain protection; 
9) gdje X je ostatak akiralne amino kiseline, navedeni amino kiselinski ostaci sekvence po izboru uključuju zaštitu bočnog lanca;
mg Distilled water for injection 
Destilirana voda za injekcije 1 ml
A method for inhibiting VR1 function in a cell in vitro comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Metoda inhibicije funkcije VRI u stanici in vitro koja sadrži dolaženje u kontakt sa stanicom, koja može eksprimirati VR1 s učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
In other words, the key combination element 26 is itself a biasing element operative to apply an urging force against the lock combination element. 
Drugim riječima, element kombinacije ključa 26 je sam po sebi pomični element koji funkcionira tako da prenosi silu na element kombinacije brave.
causing an intervention to be output that is a different biological or pharmaceutical substance than the intervention in the subset; and causing an intervention to be output that has a different amount of biological or pharmaceutical substance than the intervention in the subset. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time pokretanje intervencije kao ishoda koja je povećana u odnosu na intervenciju u podskupu, što je najmanje jedno od: pokretanja intervencije kao ishoda koja je drugačija biološka ili farmaceutska tvar nego intervencija u podskupu; i pokretanje intervencije kao ishoda koja ima različitu količinu biološke ili farmaceutske tvari nego intervencija u podskupu.
The method of claim 67, wherein the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg. 
dvolančano RNAi sredstvo se treba primjenjivati u dozi od oko 0.01 mg/kg do oko 10 mg/kg, oko 0.5 mg/kg do oko 50 mg/kg, ili oko 10 mg/kg do oko 30 mg/kg; i/ili
a test anti-tumor agent alone, 
samo s testnim protutumorskim sredstvom,
A software product recorded on non-transient machine-readable data storage media, wherein the software product is executable upon computing hardware for: 
Softverski proizvod snimljen na ne-postojanom strojno čitljivom mediju za pohranu podataka, naznačen time da se softverski proizvod može izvršiti na računalnom hardveru (100, 110) za provedbu postupka prema bilo kojem od zahtjeva 8 do 11.
The product was collected by filtration, washed with ethanol (20ml) and dried in vacuo at 50°C to give the title compound, 5.64g, 56.4%. 
Produkt se prikupi filtracijom, ispere etanolom (20 ml), te osuši u vakuumu na 50 "C kako bi se dobilo naslovni spoj, 5,64 g, 56,4 %.
where R1 is a hydroxyalkyl group having 1 to 6 C atoms and where R2 and R3 independently of one another are the stated hydroxyalkyl group or hydrogen. 
Mo do na gdje je R, hidroksialkilna skupina koja ima 1 do 6 C-atoma, i gdje su R, i Rz međusobno neovisni od navedene hidroksialkilne skupine ili vodika.
After 8 days the control bananas were mostly brown and soft to the touch whereas the coated bananas had small brown spots and the interior flesh was firm with no off flavors or odors when tasted. 
Poslije & dana kontrolne banane su većim dijelom bile smeđe i mekane na dodir, pri čemu su obložene banane imale sitne smeđe točke i unutrašnji mesnati dio je bio čvrst i bez bilo kakvog neugodnog okusa ili mirisa.